公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2014 | EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid | Yeh D.-C.; Chen D.-R.; Chao T.-Y.; Chen S.-C.; Wang H.-C.; Rau K.-M.; Feng Y.-H.; Chang Y.-C.; Lee K.-D.; Ou-Yang F.; WEN-HUNG KUO ; KING-JEN CHANG ; Lin Y.-C.; Tseng L.-M.; Hou M.-F. | In Vivo | 6 | 7 | |
2020 | A nationwide survey of fatigue in cancer patients in Taiwan: An unmet need | Rau K.-M.; Rau K.-M.; SHIOW-CHING SHUN ; Chiou T.-J.; Lu C.-H.; Lu C.-H.; Ko W.-H.; Ko W.-H.; Lee M.-Y.; Huang W.-T.; KUN-HUEI YEH ; Chang C.-S.; Chang C.-S.; Hsieh R.-K. | Japanese Journal of Clinical Oncology | 9 | 9 | |
2020 | Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors | Desai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. | Journal for ImmunoTherapy of Cancer | 87 | 73 | |
2014 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma | Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; CHIUN HSU ; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. | Clinical Cancer Research | 95 | 85 | |
2013 | Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid | Chao T.-C.; Chen D.-R.; Chao T.-Y.; Chen S.-C.; Yeh D.-C.; Wang H.-C.; Huang W.-T.; Rau K.-M.; KING-JEN CHANG ; Yang T.-L.; Lee K.-D.; Tai C.-J.; Tseng L.-M.; Hou M.-F. | Anticancer Research | 1 | ||
2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | Ryoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. | British Journal of Cancer | 21 | 17 |